Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

30 December 2011

Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT

Barbara Nasilowska-AdamskaAEF, Richard SzydloC, Piotr RzepeckiB, Anna CzyzB, Agnieszka TomaszewskaBD, Miroslaw MarkiewiczB, Tigran TorosianB, Maria BieniaszewskaB, Andrzej HellmanD, Wieslaw Wiktor JedrzejczakD, Jerzy HolowieckiD, Mieczyslaw KomarnickiD, Krzysztof WarzochaDE, Bozena MarianskaDE

Ann Transplant 2011; 16(4): 47-54 :: ID: 882218

Abstract

Background: Palifermin is known as the effective growth factor to reduce the incidence, duration and severity of oral mucositis (OM) following hematopoietic stem cell transplantation (HSCT). However, additional data on the long-term safety of palifermin and its potential influence on graft versus host disease (GvHD) are needed.
Material/Methods: In this multi-center, non-randomized, matched-control study we assessed early overall survival (OS), incidence and severity of acute/chronic GvHD (a/cGvHD) and incidence of secondary malignancies in 36 patients with hematological diseases treated with allogeneic HSCT and palifermin.
Results: The incidence of aGvHD was 28.2% and 38.4% (p=0.34) and cGvHD 41% and 53.8% (p=0.70) in the palifermin and control groups, respectively. The incidence of aGvHD grade 0–IV was 69.2%, 5.1%, 17.9%, 2.5%, 2.5% in the palifermin group and 61.5%, 12.8%, 12.8%, 10.2%, 5.2% in the control group, respectively (p>0.4 for each). The incidence of limited and extensive cGvHD was 17.9% and 23% in the palifermin versus 25.6% and 28.2% in the control group (p=0.32 and p=0.50, respectively).
The estimated 3-year OS did not differ significantly between studied groups. We did not observe any secondary malignancies in these patients.
Conclusions: Administration of palifermin doesn’t seem to influence the incidence and severity of aGvHD/cGvHD, secondary malignancies occurrence and early OS in patients undergoing allogeneic HSCT.

Keywords: Secondary malignancy, GvHD, palifermin, allogeneic HSCT

Add Comment 0 Comments

In Press

Original article  

Steroid Use in ABO-Incompatible Kidney Transplants: Withdrawal vs Maintenance

Ann Transplant In Press; DOI: 10.12659/AOT.947747  

Original article  

Intra-Arterial Contrast-Enhanced Ultrasound for Transcatheter Thrombolysis in Post-Transplant Hepatic Arter...

Ann Transplant In Press; DOI: 10.12659/AOT.947500  

Original article  

Early Atropine Protocol Enhances Dobutamine Stress Echocardiography in End-Stage Liver Disease: A Practical...

Ann Transplant In Press; DOI: 10.12659/AOT.950166  

Most Viewed Current Articles

15 Aug 2023 : Review article   7,349

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

DOI :10.12659/AOT.939750

Ann Transplant 2023; 28:e939750

03 Jan 2023 : Original article   7,205

Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...

DOI :10.12659/AOT.938467

Ann Transplant 2023; 28:e938467

16 May 2023 : Original article   7,029

Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...

DOI :10.12659/AOT.939258

Ann Transplant 2023; 28:e939258

28 May 2024 : Original article   6,629

Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...

DOI :10.12659/AOT.943281

Ann Transplant 2024; 29:e943281

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358